GENÉTICA MOLECULAR EN ONCOHEMATOLOGÍA
GlaxoSmithKline (United Kingdom)
Londres, Reino UnidoPublications en collaboration avec des chercheurs de GlaxoSmithKline (United Kingdom) (1)
2022
-
Mepolizumab Reduces Hypereosinophilic Syndrome Flares Irrespective of Blood Eosinophil Count and Interleukin-5
Journal of Allergy and Clinical Immunology: In Practice, Vol. 10, Núm. 9, pp. 2367-2374.e3